FILING ANALYSIS · MONDAY, NOVEMBER 16

Vivos Therapeutics, Inc. VVOS — 8-K: Results of Operations and Financial Condition

neutral

Vivos Therapeutics reported a 24% quarter-over-quarter revenue increase and an 18% year-over-year improvement in operating loss, but the company's cash and cash equivalents were only $0.2 million at the end of the third quarter, and the recent SOD Sciences transaction, which included a debt-for-equity exchange, may have helped regain compliance with Nasdaq's stockholders' equity requirement but al

The filing

8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+